Therapy

Adaptimmune Therapeutics

$5.60
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.18 (+3.32%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell ADAP and other stocks, options, and ETFs commission-free!

About ADAP

Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom. The listed name for ADAP is Adaptimmune Therapeutics plc American Depositary Shares.

CEO
Adrian Rawcliffe
Employees
400
Headquarters
Abingdon, Oxfordshire
Founded
2014
Market Cap
925.78M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.15M
High Today
$5.71
Low Today
$5.30
Open Price
$5.43
Volume
577.71K
52 Week High
$13.40
52 Week Low
$2.00

Collections

ADAP Earnings

-$0.33
-$0.22
-$0.11
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 25, Pre-Market

You May Also Like

CSGP
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure